MBX Biosciences, Inc. (MBX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy position MBX to challenge Yorvipath's standard-of-care status and potentially capture blockbuster revenues. MBX's early-stage obesity pipeline leverages monthly dosing and prodrug technology, targeting a massive market despite intense competition and development risk.
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks.
MBX Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 39 | $1,182.24 | $1,903.98 | $721.74 | 61.05% |
| NA Nizar Araji National Bank Of Canada /FI/ | 11 | $607.2 | $557.81 | -$49.39 | -8.13% |
| BG Bart Gancher Intech Investment Management LLC | 5,951 | $187,694.54 | $301,775.21 | $114,080.67 | 60.78% |
| CD Charlie Durham Sterling Capital Management LLC | 109 | $3,437.85 | $5,321.38 | $1,883.53 | 54.79% |
 David Kim Paradigm Biocapital Advisors LP | 2.51M | $138.44M | $124.12M | -$14.32M | -10.34% |
MBX Biosciences, Inc. (MBX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MBX Biosciences, Inc. ever had a stock split?
MBX Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steve Hoerter CEO | NASDAQ (NGS) Exchange | 55287L101 CUSIP |
| US Country | 63 Employees | - Last Dividend | - Last Split | 13 Sep 2024 IPO Date |
Overview
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company established with a focus on discovering and developing precision peptide therapies aimed at treating endocrine and metabolic disorders. Founded in 2018, the company leverages its expertise in peptide technology to craft novel treatments that address unmet medical needs within this therapeutic area. Based in Carmel, Indiana, MBX Biosciences is dedicated to advancing its portfolio of innovative drugs through clinical trials to bring new and effective therapies to patients suffering from these chronic conditions.
Products and Services
MBX Biosciences is diligently working on several promising product candidates, each at different stages of development, including:
- MBX 2109
- MBX 1416
- MBX 4291
This is the company's lead product candidate, a parathyroid hormone peptide prodrug in Phase 2 clinical trials. MBX 2109 is being developed as a potential long-acting hormone replacement therapy specifically designed for the treatment of chronic hypoparathyroidism. By addressing the hormonal imbalance, MBX 2109 aims to alleviate the symptoms and complications associated with this disorder, offering a significant improvement over current treatment options.
Currently in Phase 1 clinical trials, MBX 1416 is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist. This product candidate is designed as a potential therapy for post-bariatric hypoglycemia, a chronic and often debilitating complication of bariatric surgery. By modulating the GLP-1 pathway, MBX 1416 seeks to correct the abnormal glucose metabolism underlying this condition, thereby reducing the risk of severe hypoglycemic events following bariatric procedures.
MBX 4291 is the lead obesity product candidate, currently in investigational new drug-enabling studies. This innovative approach combines the effects of a GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug to produce a long-acting and highly potent therapy. Targeted at treating obesity and its co-morbidities, MBX 4291 aims to offer a more effective and durable solution compared to existing treatments, addressing both weight management and the metabolic disturbances associated with obesity.
Contact Information
